ONCT - Earnings call transcript Q2 2024 | Oncternal Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Richard Vincent, Chief Financial Officer. Thank you.

You may begin.

Richard Vincent

Diego. you, Thank and everyone, for us joining Good thank today. afternoon, you

XX Yazji. the Joining and are Salim quarter a ended call our our discussion on update our call and business President section filed least today. call on available Dr. will press June Breitmeyer; afternoon results of website second and James this at release days. Relations for Oncternal's financial next me XXXX earlier of a includes Dr. that the and be CMO, the were XX, Today's replay today's Investor . Today's CEO, of

certain on safe Securities Please information note under the Reform covered Litigation call the that provisions Private of discussed today's is Act. harbor

product We forward-looking cash of about during timing events interim development our will clinical call studies, and updates, this our strategies, statements and making regulatory filings planned the such be future data runway. business as our

and actual Our statements those or with in conjunction business. forward-looking the implied release differ these our in for be our with filed full considered XXXX. XX-K These by by risks associated from cautionary December filings, XX-Q ended SEC today results and XX, today's could are uncertainties year statements previously Form our should press statements forward-looking to stated and the contained due filed including materially qualified Form our and

any live update contains of this time-sensitive or date X, August broadcast, XXXX. circumstances this statements of as to occurring We events of revise or call This no the date information that only to is call. the after undertake obligation reflect accurate forward-looking

our Breitmeyer. CEO, pleasure my to Jim is the hand over it that, to call With Dr.

James Breitmeyer

advance are investigators. unmet androgen the and programs cancers and dose study, from fortune ONCT-XXX, novel medical good the for demand or to afternoon, patients of escalation through action we advancing first-in-class see X clinical strong significant I/II Rich, targeting inhibitor, continues dual continue Thank Phase needs. we our DAARI, with to receptor everyone. At you, Oncternal,

mechanism, receptor, prone ONCT-XXX-inhibited of the androgen studies and induced showed terminal binding As domain end reminder, cancer as LBD this it that prostate the receptor. ligand androgen from both degradation such variants cells which a key believe cancer preclinical include and enzalutamide inhibitors, currently ONCT-XXX the at also as mechanisms and, AR through to of such approved address Thanks the well as pathway multiple novel set domain ARDX. mutations as splice we may

The trial well. is proceeding clinical

not study of that observed announced have cohort other side dose-limiting dosing the fully And We any is or we the toxicities concerning sixth now effects. enrolled. recently

milligrams this the per X,XXX ONCT-XXX to after day. was Patients review from move committee to third of treated data milligrams once the level dose date, made XXX study's including decision in daily. receiving XXX cohort administered orally safety this reviewing The patients of to are dose the level by

in clinical an third for share quarter. data plan initial We ONCT-XXX to the later update

Now switching ONCT-XXX, autologous targeting to RORX gears our CAR-T product.

I/II who with patients is in including relapsed aggressive previous in or Our refractory lymphoma, Phase treatment CAR-T have study failed enrolling patients. CDXX treating B-cell patients

cohort. current dose-limiting no have There observed been the dosing toxicities in

dosing new results, We from of patients fourth XXXX. expect including updated the with in schedule to data clinical report the treated quarter

call back Rich now I to this, With CFO, the Rich? turn Vincent. our

Richard Vincent

Thank you, Jim.

is received derived grants NIH. revenue development from the and Our from currently research

was second ended for revenue quarter June XXXX. million grant Our $X.X the XX,

million, million . Research for Net for expenses million. $X.X administrative totaled net expenses in million operating total was including stock-based $X.X $X.X ended per $X.XX of $X.X noncash Our expenses XXXX, for diluted. and the $X.X and the million, second and share development a general loss quarter June expense. basic XX, second quarter were loss compensation and totaled

first to and cash, funds support believe stock XXXX. outstanding, debt. be the million investments will X We quarter $XX.X million XXXX, these of cash equivalents XX, June into no shares As of we short-term sufficient common in approximately and our had operations of

respect to fourth ONCT-XXX, quarter data the expect forward milestones, the present DAARI of lead candidate, XXXX. we third data we in readouts following initial For With to looking to the with our upcoming product clinical quarter updates: are in XXXX, additional of

CAR-T, quarter expect our ONCT-XXX, update data autologous a to report RORX XXXX. the in of clinical we For fourth

that, back to Q&A this With the the call. portion operator things for I of will turn earning Diego? over

Operator

[Operator Instructions]

And question Markets. comes with Northland our first from Capital Byrnes Carl

Carl Byrnes

for if expect through would be cohorts? And should expecting have inclusive to safety would the first data, progress. be PSA clinical on then With well. which be so, be And expecting the or of we third what X,XXX reduction or that there? quarter as potentially specific, Congratulations the in you the the I what's cohorts respect a milligram XXX the late -- we to what data numbers? . quarter also third -- So update would follow-up be dose, all do

James Breitmeyer

Salim. ahead, Go

Salim Yazji

Carl. Yes,

in follow-up So the regards I for probably we data be early not the based because a safety plus would too sure of effect, to mean present would be period with long. PSA parameters to on what ones we expect some will will and

Carl Byrnes

Great. And in clinical fourth that... what might additional the then the data quarter,

Salim Yazji

data I have. first probably a if additional longer more mean of will So follow-up, we clinical the the in quarter, be more cohorts,

think advanced third than in be we're showing what more we'll going the be quarter. I So to

Carl Byrnes

with patients, many in you quarter, been in anticipate Got have then update XXX, be it. finally, enrolled how cover? you respect many that could And with might to the that fourth if subjects the how disclose,

James Breitmeyer

Carl, enrolled we I disclosed the regimen dosing cells. we CAR-T, the dosing and we're not revised active, the deck, show the our the any in we under CAR-T think we toxicity. But which on as active and yet. found scheme, very amended seeing as we have patients with dose-limiting T revised corporate And know haven't enrollment were you very program

Operator

. question Our with Capital Dolliver Kemp comes from Brookline Markets. next

Brian Kemp Dolliver

higher to With XXX sixth get possibility the cohorts is cohort? particularly but regard after admittedly speculative, from you Great. question dosing this data, and to any is would move there you the

James Breitmeyer

it's Kemp, question. great So a

And data lot of so we're collecting these patients. a on

novel the efficacy and got interesting biomarker we so work we're of the have then, And and some that safety. and We've doing pharmacokinetic course, data.

any dose for will committee available about on decisions the levels the review made be data. of based additional totality scientific cohorts so And with

Brian Kemp Dolliver

there theme, practical regard go again, are Okay. administration the That's doses? with helpful. you any And higher if to then, same limits on to

James Breitmeyer

-- have if perfectly so data a a to more XXX-milligram -- go feasible X we it day give for we're tablet that tablets we is So suggests than the using and higher. should

Operator

And questions there time. are hand further I'll James Dr. floor at to this remarks. no Breitmeyer closing back for the

James Breitmeyer

Thank you, Diego.

clinical remain you are with can you updates Phase and in I from months. programs as forward we results to looking our clinical So with data encouraged coming tell, the the

Thank throughout thank today, to us and for So we to this look afternoon. you, good joining year. I'd and forward like updating you you

Operator

today's a evening. parties Have disconnect. This All conference. may concludes great

Oncternal Therapeutics (ONCT) 8 Aug 242024 Q2 Earnings call transcript